Reduced anti-oxidant and increased inflammatory status in interstitial lung diseases (ILD)

A. Boots, M. Drent, A. Bast, G. Haenen (Maastricht, Netherlands)

Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Boots, M. Drent, A. Bast, G. Haenen (Maastricht, Netherlands). Reduced anti-oxidant and increased inflammatory status in interstitial lung diseases (ILD). Eur Respir J 2007; 30: Suppl. 51, 774

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Elevated alveolar antioxidant levels in chronic fibrosing interstitial lung diseases
Source: Annual Congress 2008 - New therapeutic strategies in idiopathic pulmonary fibrosis
Year: 2008


Increased CCL18 production in interstitial lung diseases is associated with fibrosis
Source: Eur Respir J 2004; 24: Suppl. 48, 38s
Year: 2004

TNFα and INFγ inducing capacity of sera from interstitial lung diseases (ILD) patients in relation to its angiogenic activity
Source: Eur Respir J 2001; 18: Suppl. 33, 410s
Year: 2001

Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease
Source: International Congress 2016 – ILD pathogenesis
Year: 2016

COPD is associated with reduced pulmonary interstitial expression of pentraxin-3
Source: Eur Respir J 2012; 39: 830-838
Year: 2012



Increasing oxidative stress and inflammation in patients with exacerbated chronic obstructive pulmonary disease (COPD) and their association with lung function
Source: Annual Congress 2012 - The smoking gun in COPD biology
Year: 2012


Alveolar lymphocytes (AL) apoptosis in interstitial lung diseases (ILD). Increased AL apoptosis rate in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis
Year: 2009


How systemic inflammatory diseases affect the lung
Source: Virtual Congress 2020 – Interstitial lung diseases
Year: 2020


Prevalence and trafficking of circulating fibrocytes in smoking-related fibrogenic lung diseases
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015

Effect of nintedanib on the release of angiogenic/angiostatic cytokines by alveolar macrophages (AMs) in interstitial lung diseases (ILD)
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015

Increased levels of oxidative stress markers in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016


Serum surfactant protein D is a potential biomarker of lung damage in systemic sclerosis
Source: International Congress 2016 – Connective tissue disorders
Year: 2016


Relationships between angiogenic activity of sera from interstitial lung disease (ILD) patients and lung function tests
Source: Eur Respir J 2002; 20: Suppl. 38, 106s
Year: 2002

Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases
Year: 2013


Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease
Source: International Congress 2016 – Clinical aspects of ILD
Year: 2016


Increased lung apoptosis and expression of ceramide in subjects with chronic obstructive pulmonary disease (COPD)
Source: Annual Congress 2009 - COPD: basic science and clinical studies
Year: 2009

High-dose N-acetylcysteine (NAC) in fibrotic interstitial lung diseases, a retrospective analysis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease I
Year: 2013

Lysozyme level and activity are decreased in the lungs of patients with idiopathic pulmonary fibrosis (IPF) and potentially contribute to increased susceptibility to pulmonary infection
Source: Annual Congress 2006 - Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases
Year: 2006


KL-6, SP-D and MMP-7 as serum biomarkers for early detection of interstitial lung diseases
Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease
Year: 2013